3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
13
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Mantle-Cell
7
Lymphoma, Non-Hodgkin
5
Waldenstrom Macroglobulinemia
4
Neoplasms
3
Lymphoma
3
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Hairy Cell
2
Burkitt Lymphoma
2
Bronchiolitis Obliterans Syndrome
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Central Nervous System Lymphoma (PCNSL)
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Myeloid, Acute
1
Leukemia, B-Cell
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Anemia
1
Interventions
Cyclophosphamide
14
fludarabine
8
Rituximab
6
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Vincristine
4
Doxorubicin
4
Dexamethasone
4
zanubrutinib
3
Prednisone
3
Nivolumab
3
Etoposide
3
tazemetostat
2
tafasitamab
2
pirtobrutinib
2
pembrolizumab
2
glofitamab
2
etoposide phosphate
2
cemiplimab
2
acalabrutinib
2
Leukapheresis
2
Immunotherapy, Adoptive
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cisplatin
2
Cell- and Tissue-Based Therapy
2
Biopsy
2
venetoclax
1
varlilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
ibrutinib
×
30 days
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled